Beyond killing: Can we find new ways to manage infection?

Evolution, Medicine and Public Health

Volumn 2016, Issue 1, 2016, Pages 148-157

  Vale, Pedro F ^a   McNally, Luke ^a   Doeschl Wilson, Andrea ^b   King, Kayla C ^c   Popat, Roman ^a   Domingo Sananes, Maria R ^d   Allen, Judith E ^a   Soares, Miguel P ^e   Kümmerli, Rolf ^f  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d UNIVERSITÉ DE RENNES 1   (France)

^e INSTITUTO GULBENKIAN DE CIÊNCIA   (Portugal)

^f UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

Anti virulence drugs; Damage limitation; Disease tolerance; Evolution; Infection; Microbiota

Indexed keywords

ANTIBIOTIC AGENT; PENICILLIN DERIVATIVE; VIRULENCE FACTOR;

ANTIBIOTIC SENSITIVITY; BACTERIAL INFECTION; BACTERIAL TRANSMISSION; BACTERIAL VIRULENCE; BACTERIUM ADHERENCE; COMMENSAL; DISEASE SEVERITY; DRUG EFFECT; HUMAN; NONHUMAN; NOTE; POPULATION RESEARCH; PRIORITY JOURNAL; QUORUM SENSING; TISSUE INJURY;

EID: 85028348971     PISSN: None     EISSN: 20506201     Source Type: Journal    
DOI: 10.1093/EMPH/EOW012     Document Type: Note

References (70)

1. Levy SB, Marshall B. Antibacterial resistance worldwide: causes, challenges and responses. Nat Med 2004;10: S122-9
2. Schäberle TF, Hack IM. Overcoming the current deadlock in antibiotic research. Trends Microbiol 2014;22:165-7
3. Roberts JP. Incentives aim to boost antibiotic development. Nat Biotechnol 2012;30:735
4. Genilloud O, Vicente F. Strategies to Discover Novel Antimicrobials to Cope with Emerging Medical Needs. In: Marinelli F, Genilloud O (eds.). Antimicrobials. Springer: Berlin Heidelberg, 2014, 327-60
5. Cha JY, Ishiwata A, Mobashery S. A novel beta-lactamase activity from a penicillin-binding protein of Treponema pallidum and why syphilis is still treatable with penicillin. J Biol Chem 2004;279:14917-21
6. Horn DL, Zabriskie JB, Austrian R et al. Why have group a streptococci remained susceptible to penicillin? Report on a symposium. Clin Infect Dis 1998;26:1341-5
7. Yeh PJ, Hegreness MJ, Aiden AP et al. Drug interactions and the evolution of antibiotic resistance. Nat Rev Microbiol 2009;7:460
8. Andersson DI,Hughes D. Antibiotic resistance and its cost: is it possible to reverse resistance? Nat Rev Microbiol 2010;8:260-71
9. Vale PF, Fenton A, Brown SP. Limiting damage during infection: lessons from infection tolerance for novel therapeutics. PLoS Biol 2014;12:e1001769
10. McClure NS, Day T. A theoretical examination of the relative importance of evolution management and drug development for managing resistance. Proc R Soc B Biol Sci 2014;281:20141861
11. Tanner EJ, Liu H, Oberste MS et al. Dominant drug targets suppress the emergence of antiviral resistance. eLife 2014;3:e03830
12. Allen RC, Popat R, Diggle SP et al. Targeting virulence: can we make evolution-proof drugs? Nat Rev Microbiol 2014; 12:300-8
13. Baron C. Antivirulence drugs to target bacterial secretion systems. Curr Opin Microbiol 2010;13:100-5
14. RaskoDA, SperandioV.Anti-virulence strategies to combat bacteria-mediated disease. Nat Rev Drug Discov 2010;9:117-28
15. Valle J, Re SD, Henry N et al. Broad-spectrum biofilm inhibition by a secreted bacterial polysaccharide. Proc Natl Acad Sci USA 2006;103:12558-63
16. Bender KO, Garland M, Ferreyra JA et al. A small-molecule antivirulence agent for treating Clostridium difficile infection. Sci Transl Med 2015;7:306ra148
17. Liu C-I, Liu GY, Song Y et al. A cholesterol biosynthesis inhibitor blocks Staphylococcus aureus virulence. Science 2008;319:1391-4
18. Ross-Gillespie A, Weigert M, Brown SP et al. Galliummediated siderophore quenching as an evolutionarily robust antibacterial treatment. Evol Med Public Health 2014;2014:18-29
19. Schlievert PM, Kelly JA. Clindamycin-induced suppression of toxic-shock syndrome-associated exotoxin production. J Infect Dis 1984;149:471
20. Imperi F, Leoni L, Visca P. Antivirulence activity of azithromycin in Pseudomonas aeruginosa. Antimicrob Resist Chemother 2014;5:178
21. Imperi F, Massai F, Facchini M et al. Repurposing the antimycotic drug flucytosine for suppression of Pseudomonas aeruginosa pathogenicity. Proc Natl Acad Sci USA 2013;110:7458-63
22. Pepper JW. Drugs that target pathogen public goods are robust against evolved drug resistance. Evol Appl 2012;5:757-61
23. Pepper JW. Defeating pathogen drug resistance: guidance from evolutionary theory. Evol Int J Org Evol 2008;62: 3185-91
24. Mellbye B, Schuster M. The sociomicrobiology of antivirulence drug resistance: a proof of concept. mBio 2011;2:e00131-11
25. Fernandez L, Hancock REW. Adaptive and mutational resistance: role of porins and efflux pumps in drug resistance. Clin Microbiol Rev 2012;25:661-81
26. LaSarre B, Federle MJ. Exploiting quorum sensing to confuse bacterial pathogens. Microbiol Mol Biol Rev MMBR 2013;77:73-111
27. Soares MP, Gozzelino R, Weis S. Tissue damage control in disease tolerance. Trends Immunol 2014;35:483-94
28. Medzhitov R, Schneider DS, Soares MP. Disease tolerance as a defense strategy. Science 2012;335:936-41
29. Ayres JS, Schneider DS. Tolerance of Infections. Annu Rev Immunol 2012;30:271-94
30. Råberg L, Graham AL, Read AF. Decomposing health: tolerance and resistance to parasites in animals. Philos Trans R Soc Lond B Biol Sci 2009;364:37-49
31. Larsen R, Gozzelino R, Jeney V et al. A central role for free heme in the pathogenesis of severe sepsis. Sci Transl Med 2010;2:51ra71
32. Ferreira A, Marguti I, Bechmann I et al. Sickle hemoglobin confers tolerance to plasmodium infection. Cell 2011;145: 398-409
33. Jamieson AM, Pasman L, Yu S et al. Role of tissue protection in lethal respiratory viral-bacterial coinfection. Science 2013;340:1230-4
34. Figueiredo N, Chora A, Raquel H et al. Anthracyclines induce DNA damage response-mediated protection against severe sepsis. Immunity 2013;39:874-84
35. O'Shea TJ, Cryan PM, Cunningham AA et al. Bat flight and zoonotic viruses. Emerg Infect Dis 2014;20:741-5
36. Brook CE, Dobson AP. Bats as "special" reservoirs for emerging zoonotic pathogens. Trends Microbiol 2015;23:172-80
37. Simms E. Defining tolerance as a norm of reaction. Evol Ecol 2000;14:563-70
38. Råberg L, Sim D, Read AF. Disentangling genetic variation for resistance and tolerance to infectious diseases in animals. Science 2007;318:812-4
39. Lough G, Kyriazakis I, Bergmann S et al. Health trajectories reveal the dynamic contributions of host genetic resistance and tolerance to infection outcome. Proc R Soc B 2015;282:20152151
40. Schneider DS. Tracing Personalized Health Curves during Infections. PLoS Biol 2011;9:e1001158
41. Doeschl-Wilson AB, Bishop SC, Kyriazakis I et al. Novel methods for quantifying individual host response to infectious pathogens for genetic analyses. Front Livest Genomics 2012;3:266
42. Gause WC, Wynn TA, Allen JE. Type 2 immunity and wound healing: evolutionary refinement of adaptive immunity by helminths. Nat Rev Immunol 2013;13:607-14
43. Allen JE, Wynn TA. Evolution of Th2 immunity: a rapid repair response to tissue destructive pathogens. PLoS Pathog 2011;7:e1002003
44. Allen JE, Sutherland TE. Host protective roles of type 2 immunity: parasite killing and tissue repair, flip sides of the same coin. Semin Immunol 2014;26:329-40
45. Alizon S, Hurford A, MideoNet al. Virulence evolution and the trade-off hypothesis: history, current state of affairs and the future. J Evol Biol 2009;22:245-59
46. Gopinath S, Lichtman JS, BouleyDMet al. Role of diseaseassociated tolerance in infectious superspreaders. Proc Natl Acad Sci USA 2014;111:15780-5
47. Miller MR, White A, Boots M. The evolution of parasites in response to tolerance in their hosts: the good, the bad, and apparent commensalism. Evol Int JOrg Evol 2006;60:945-56
48. Brown SP, Cornforth DM, Mideo N. Evolution of virulence in opportunistic pathogens: generalism, plasticity, and control. Trends Microbiol 2012;20:336-42
49. Clemente JC, Ursell LK, Parfrey LW et al. The impact of the gut microbiota on human health: an integrative view. Cell 2012;148:1258-70
50. Dillon RJ, Vennard CT, Charnley AK. Exploitation of gut bacteria in the locust. Nature 2000;403:851
51. Koch H, Schmid-Hempel P. Socially transmitted gut microbiota protect bumble bees against an intestinal parasite. Proc Natl Acad Sci USA 2011;108:19288-92
52. Rawls JF, MahowaldMA, Ley RE et al. Reciprocal gut microbiota transplants from zebrafish and mice to germ-free recipients reveal host habitat selection. Cell 2006;127:423-33
53. Yilmaz B, Portugal S, Tran TM et al. Gut microbiota elicits a protective immune response against malaria transmission. Cell 2014;159:1277-89
54. Brown SP, Fredrik Inglis R, Taddei F. SYNTHESIS: Evolutionary ecology of microbial wars: within-host competition and (incidental) virulence. Evol Appl 2009;2:32-9
55. Lau GW, Hassett DJ, Ran H et al. The role of pyocyanin in Pseudomonas aeruginosa infection. Trends Mol Med 2004;10:599-606
56. Lysenko ES, Ratner AJ, Nelson AL et al. The role of innate immune responses in the outcome of interspecies competition for colonization of mucosal surfaces. PLoS Pathog 2005;1:e1
57. Stecher B, Robbiani R, WalkerAWet al. Salmonella enterica serovar typhimurium exploits inflammation to compete with the intestinal microbiota. PLoS Biol 2007;5:2177-89
58. Mueller UG, Sachs JL. Engineering microbiomes to improve plant and animal health. Trends Microbiol 2015; 23:606-17
59. Moreno MA, Furtner F, Rivara FP. Clostridium difficile: a cause of diarrhea in children. JAMA Pediatr 2013;167:592
60. Ryan, KJ, Ray CG. (eds.). Sherris Medical Microbiology: An Introduction to Infectious Diseases, 4th edn. New York: McGraw-Hill Medical
61. Burke KE, Lamont JT. Fecal transplantation for recurrent Clostridium difficile infection in older adults: a review. J Am Geriatr Soc 2013;61:1394-8
62. van Nood E, Vrieze A, Nieuwdorp M et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med 2013;368:407-15
63. Buffie CG, Bucci V, Stein RR et al. Precision microbiome reconstitution restores bile acid mediated resistance to Clostridium difficile. Nature 2015;517:205-8
64. Kommineni S, Bretl DJ, Lam V et al. Bacteriocin productionaugmentsnichecompetitionbyenterococci inthemammalian gastrointestinal tract. Nature 2015;526:719-22
65. Libberton B, Horsburgh MJ, Brockhurst MA. The effects of spatial structure, frequency dependence and resistance evolution on the dynamics of toxin-mediated microbial invasions. Evol Appl 2015;8:738-50
66. King KC, Brockhurst MA, Vasieva O et al. Rapid evolution of microbe-mediated protection against pathogens in a worm host. ISME J 2016, March. http://dx.doi.org/10. 1038/ismej.2015.259
67. Duan F, March JC. Engineered bacterial communication prevents Vibrio cholerae virulence in an infant mouse model. Proc Natl Acad Sci USA 2010;107:11260-4
68. Schieber AMP, Lee YM, Chang MW et al. Disease tolerance mediated by microbiome E. coli involves inflammasome and IGF-1 signaling. Science 2015;350:558-63
69. McNally L, Vale PF,BrownSP.Microbiome engineering could select for more virulent pathogens. bioRxiv 2015;027854, September. doi:10.1101/027854
70. Oliveira NM, Martinez-Garcia E, Xavier J et al. Biofilm formation as a response to ecological competition. PLoS Biol 2015;13:e1002191